C
엑세스바이오
950130KOSDAQ의료용품 및 기타 의약 관련제품 제조업45.0 / 100
Reference Date: 2026-04-13
Financial Score17.5 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Slightly down 3.1% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
AccessBio develops and sells diagnostic products based on in-vitro diagnostics (IVD) technologies, focusing on infectious disease rapid diagnostic tests (RDTs) for malaria, influenza, and COVID-19. Its COVID-19 diagnostic products, which received FDA Emergency Use Authorization, have become a major revenue driver, with the company expanding globally amid growing IVD market demand.
Number of Employees
75people
Average Salary
159.0M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 19.894.0Point
PBR
—Industry Average 1.623.5Point
ROE
-14.02Industry Average -4.893.5Point
2.9x industry avg (excellent)
Debt Ratio
4.40Industry Average 8.886.5Point
Half of industry avg (excellent)
Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼71.2% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼727.6% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -5.0% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (9%, downtrend)
Current 2,990Won52-week high 5,56952-week low 2,725
1-month return2.0Point
1m -3.08% (slight drop)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
7 totalPositive 0Neutral 7Negative 0
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
- Neutral정기주주총회결과2026-03-31
- Neutral본점소재지변경2026-03-31
- Neutral[기재정정]타법인주식및출자증권취득결정2026-03-27
- Neutral[기재정정]감사보고서제출2026-03-24